Post transplant lymphoproliferative disorder: Difference between revisions
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
'''Post-transplant lymphoproliferative disorder''' (also known as '''PTLD''') is defined as a [[B-cell]] proliferation due to therapeutic immunosuppression after organ transplantation. Patients with post-transplant lymphoproliferative disorder may develop infectious mononucleosis-like lesions or polyclonal polymorphic B-cell hyperplasia. In some cases, [[B-cells]] may undergo mutations which will render them malignant, giving rise to a [[lymphoma]]. The malignant cell clone can become the dominant proliferating cell type, leading to a group of [[B cell]] [[lymphoma]]s occurring in [[Immunosuppression|immunosuppressed]] patients following [[organ transplant]]. | |||
==Historical Perspective== | ==Historical Perspective== | ||
Line 12: | Line 13: | ||
==Classification== | ==Classification== | ||
* | *There is no classification for post transplant lymphoproliferative disorder. | ||
==Pathophysiology== | ==Pathophysiology== | ||
Line 22: | Line 20: | ||
*The has been associated with the development of post transplant lymphoproliferative disorder. | *The has been associated with the development of post transplant lymphoproliferative disorder. | ||
*On gross pathology, | *On gross pathology, characteristic findings of post transplant lymphoproliferative disorder, include: | ||
*On microscopic histopathological analysis, | *On microscopic histopathological analysis, characteristic findings of post transplant lymphoproliferative disorder, include: | ||
==Causes== | ==Causes== |
Revision as of 20:44, 23 May 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Synonyms and keywords: PTLD;
Overview
Post-transplant lymphoproliferative disorder (also known as PTLD) is defined as a B-cell proliferation due to therapeutic immunosuppression after organ transplantation. Patients with post-transplant lymphoproliferative disorder may develop infectious mononucleosis-like lesions or polyclonal polymorphic B-cell hyperplasia. In some cases, B-cells may undergo mutations which will render them malignant, giving rise to a lymphoma. The malignant cell clone can become the dominant proliferating cell type, leading to a group of B cell lymphomas occurring in immunosuppressed patients following organ transplant.
Historical Perspective
- Post transplant lymphoproliferative disorder was first discovered by Denis Parsons Burkitt, an Irish physician, in 1965.
Classification
- There is no classification for post transplant lymphoproliferative disorder.
Pathophysiology
- The pathogenesis of post transplant lymphoproliferative disorder is characterized by:
- The has been associated with the development of post transplant lymphoproliferative disorder.
- On gross pathology, characteristic findings of post transplant lymphoproliferative disorder, include:
- On microscopic histopathological analysis, characteristic findings of post transplant lymphoproliferative disorder, include:
Causes
- Common causes of post transplant lymphoproliferative disorder, include:
Differentiating Post Transplant Lymphoproliferative Disorder from Other Diseases
- Post transplant lymphoproliferative disorder must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
- [Differential dx1]
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics
- The prevalence of post transplant lymphoproliferative disorder is approximately [number or range] per 100,000 individuals worldwide.
Age
- Post transplant lymphoproliferative disorder is more commonly observed among patients aged [age range] years old.
- Post transplant lymphoproliferative disorder is more commonly observed among [elderly patients/young patients/children].
Gender
- Post transplant lymphoproliferative disorder affects men and women equally.
Race
- There is no racial predilection for post transplant lymphoproliferative disorder.
Risk Factors
- Common risk factors in the development of post transplant lymphoproliferative disorder are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Natural History, Complications and Prognosis
- The majority of patients with post transplant lymphoproliferative disorder remain asymptomatic for [duration/years].
- Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
- If left untreated, patients with post transplant lymphoproliferative disorder may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of post transplant lymphoproliferative disorder include [complication 1], [complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with post transplant lymphoproliferative disorder is approximately [#%].
Diagnosis
Symptoms
- Post transplant lymphoproliferative disorder is usually asymptomatic.
- Symptoms of post transplant lymphoproliferative disorder may include the following:
- [symptom 1]
- [symptom 2]
- [symptom 3]
- [symptom 4]
- [symptom 5]
- [symptom 6]
Physical Examination
- Patients with post transplant lymphoproliferative disorder usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- There are no specific laboratory findings associated with post transplant lymphoproliferative disorder.
Imaging Findings
- There are no imaging findings associated with post transplant lymphoproliferative disorder.
Treatment
Medical Therapy
- There is no treatment for post transplant lymphoproliferative disorder; the mainstay of therapy is supportive care.
Surgery
- Surgery is not recommended for patients with post transplant lymphoproliferative disorder.
Prevention
- There are no primary preventive measures available for post transplant lymphoproliferative disorder.